Close Menu

NEW YORK – As the COVID-19 pandemic continues to stress healthcare systems across the US and world, clinical labs and diagnostic firms have raced to ramp up SARS-CoV-2 test volumes.

But while demand for SARS-CoV-2 has soared, volume for non-COVID-19 testing has plummeted as patients are putting off elective procedures and routine doctor's visits.

This week, Quest Diagnostics filed a form 8-K in which it noted that during the last two weeks of March the company's test volumes, inclusive of COVID-19 tests, declined by more than 40 percent.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.


As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Sponsored by

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.